Biotech · Public company · San Diego, CA, US

ImmunityBio, Inc.

Ticker IBRX · SEC CIK 0001326110

Track this companyFree. Adds ImmunityBio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2520 recruiting or active

Pipeline programs54From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline54

Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAIPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAIPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAIPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
DocetaxelPhase 3 · NSCLC Stage IVClinicalTrials.gov · fetched Nov 12, 2026
N-803Phase 3 · NSCLC Stage IVClinicalTrials.gov · fetched Nov 12, 2026
N-803Phase 3 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 and BCGPhase 3 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
NAI + Nivolumab + IpilimumabPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
NAI + PembrolizumabPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or PaclitaxelPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Prior failed checkpoint inhibitorPhase 3 · NSCLC Stage IVClinicalTrials.gov · fetched Nov 12, 2026
TislelizumabPhase 3 · NSCLC Stage IVClinicalTrials.gov · fetched Nov 12, 2026
Aldoxorubicin HClPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
AnktivaPhase 2 · Long COVIDClinicalTrials.gov · fetched Nov 12, 2026
BCG (50mg/instillation)Phase 2 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
BCG (50mg/instillation) + N-803 (400 μg/instillation)Phase 2 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
BevacizumabPhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Gemcitabine (GEM)Phase 2 · Advanced Pancreatic CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
HCW9218Phase 2 · Advanced Pancreatic CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Intravesical Recombinant Mycobacterium (rMBCG)Phase 2 · NMIBCClinicalTrials.gov · fetched Nov 12, 2026
M-CENKPhase 2 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803Phase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803Phase 2 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803Phase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
N-803 (IL-15 Superagonist)Phase 2 · Long COVIDClinicalTrials.gov · fetched Nov 12, 2026
N-803 + AtezolizumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 + AvelumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 + DurvalumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 + NivolumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 + PembrolizumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
N-803 + Pembrolizumab + PD-L1 t-haNKPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Nab-paclitaxelPhase 2 · Advanced Pancreatic CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Nab-paclitaxelPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
PD-L1 t-haNKPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
PD-L1 t-haNKPhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
Tumor Treating Fields (TTFields, 200 kHz)Phase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
Apheresis collection of MNCs (part A)Phase 1 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
CD19t-haNK suspensionPhase 1 · Non Hodgkin's Lymphoma Refractory/RelapsedClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Non Hodgkin's Lymphoma Refractory/RelapsedClinicalTrials.gov · fetched Nov 12, 2026
enfortumab vedotin (EV)Phase 1 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Non Hodgkin's Lymphoma Refractory/RelapsedClinicalTrials.gov · fetched Nov 12, 2026
IBRX-042Phase 1 · HPV-Related CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)Phase 1 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
N-803 (Cohort 2 part B)Phase 1 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
N803Phase 1 · Non Hodgkin's Lymphoma Refractory/RelapsedClinicalTrials.gov · fetched Nov 12, 2026
Nogapendekin Alfa Inbakicept (NAI)Phase 1 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
PD-L1 t-haNKPhase 1 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 1 · Non Hodgkin's Lymphoma Refractory/RelapsedClinicalTrials.gov · fetched Nov 12, 2026
N803 plus Bacillus Calmette-Guerin (BCG)Non Muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
rMBCGNMIBCClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerPHASE1 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07217496 · fetched Nov 12, 2026
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerPHASE1 · NOT_YET_RECRUITING · started Nov 30, 2026ClinicalTrials.gov NCT07756593 · fetched Nov 12, 2026
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Jul 7, 2026ClinicalTrials.gov NCT07355205 · fetched Nov 12, 2026
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasPHASE1 · WITHDRAWN · started Feb 1, 2026ClinicalTrials.gov NCT07049432 · fetched Nov 12, 2026
A Study to Assess Anktiva in Patients With Long Covid-19.PHASE2 · RECRUITING · started Nov 14, 2025ClinicalTrials.gov NCT07108036 · fetched Nov 12, 2026
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGPHASE1_PHASE2 · RECRUITING · started Oct 15, 2025ClinicalTrials.gov NCT06800963 · fetched Nov 12, 2026
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyPHASE3 · RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT06745908 · fetched Nov 12, 2026
A Study to Examine Anktiva for the Treatment of COVID-19.PHASE2 · RECRUITING · started Sep 4, 2025ClinicalTrials.gov NCT07123727 · fetched Nov 12, 2026
Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaPHASE1 · RECRUITING · started Aug 22, 2025ClinicalTrials.gov NCT05618925 · fetched Nov 12, 2026
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerPHASE2 · RECRUITING · started Nov 6, 2024ClinicalTrials.gov NCT06710288 · fetched Nov 12, 2026
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT06061809 · fetched Nov 12, 2026
IBRX-042 In Participants With HPV-Associated TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 14, 2024ClinicalTrials.gov NCT05976828 · fetched Nov 12, 2026
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCPHASE2 · RECRUITING · started Feb 16, 2024ClinicalTrials.gov NCT06239220 · fetched Nov 12, 2026
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)ACTIVE_NOT_RECRUITING · started Aug 17, 2023ClinicalTrials.gov NCT05981131 · fetched Nov 12, 2026
HCW9218 for Advanced Pancreatic CancerPHASE1_PHASE2 · COMPLETED · started Oct 17, 2022ClinicalTrials.gov NCT05304936 · fetched Nov 12, 2026
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 21, 2021ClinicalTrials.gov NCT04898543 · fetched Nov 12, 2026
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 21, 2020ClinicalTrials.gov NCT04390399 · fetched Nov 12, 2026
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersPHASE1 · COMPLETED · started Jul 18, 2019ClinicalTrials.gov NCT04050709 · fetched Nov 12, 2026
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 11, 2018ClinicalTrials.gov NCT03228667 · fetched Nov 12, 2026
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerPHASE3 · TERMINATED · started May 18, 2018ClinicalTrials.gov NCT03520686 · fetched Nov 12, 2026
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 21, 2017ClinicalTrials.gov NCT03317158 · fetched Nov 12, 2026
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 2, 2017ClinicalTrials.gov NCT03022825 · fetched Nov 12, 2026
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell TransplantationPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2017ClinicalTrials.gov NCT02782546 · fetched Nov 12, 2026
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 21, 2014ClinicalTrials.gov NCT02138734 · fetched Nov 12, 2026
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerAVAILABLEClinicalTrials.gov NCT06810141 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 14, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 9, 2026 · fetched Nov 12, 2026